Literature DB >> 23551460

Long-term efficacy and safety of two different rhythm control strategies in elderly patients with symptomatic persistent atrial fibrillation.

Alessandro Blandino1, Elisabetta Toso, Marco Scaglione, Matteo Anselmino, Federico Ferraris, Davide Sardi, Alberto Battaglia, Fiorenzo Gaita.   

Abstract

BACKGROUND: We prospectively compared the efficacy, safety, and quality of life (QoL) impact of catheter ablation versus antiarrhythmic drugs (AAD) in elderly patients with persistent atrial fibrillation (AF). METHODS AND
RESULTS: Four hundred and twelve consecutive patients, aged ≥ 70 years, underwent ablation (Group A, 153 patients) or AAD (Group B, 259 patients). Study endpoints: treatment failure (any AF/AT lasting >30 seconds) and treatment-related adverse events (acute when ≤1 month of procedure and long term when >1 month). At a follow-up of 60 ± 17 months, 43% and 46% patients in Group B versus 58% and 76% in Group A were in sinus rhythm (SR), respectively, after one (P = 0.003) and 2 procedures (P < 0.001). Fifteen acute adverse events occurred (6.7% in Group A vs 1% in Group B, P < 0.001), mainly periprocedural cerebral thromboembolism (3.3% in Group A vs 0.7% in Group B, P = 0.058). Previous TIA/stroke resulted the only independent predictor of periprocedural cerebrovascular accidents (OR 1.2, 95%IC 1.1-1.3). At follow-up, 74 long-term adverse events occurred (7.7% in Group A vs 23.9% in Group B, P < 0.001) with Group B patients more often experiencing AAD-related adverse events (12.7% vs 2.6%, P < 0.001). Group A and absence of AF/AT recurrences significantly improved QoL scores (P < 0.001).
CONCLUSIONS: In elderly persistent AF patients, catheter ablation is more effective in maintaining SR and in improving QoL than AAD but is affected by a higher risk of embolic complications, particularly in patients with previous TIA/stroke. Over time, Group A patients more likely discontinued AAD with a reduction of long-term adverse events.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  antiarrhythmic drugs; catheter ablation; elderly patients; persistent atrial fibrillation; quality of life; stroke

Mesh:

Substances:

Year:  2013        PMID: 23551460     DOI: 10.1111/jce.12126

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  15 in total

1.  Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).

Authors:  Benjamin A Steinberg; Sunghee Kim; Gregg C Fonarow; Laine Thomas; Jack Ansell; Peter R Kowey; Kenneth W Mahaffey; Bernard J Gersh; Elaine Hylek; Gerald Naccarelli; Alan S Go; James Reiffel; Paul Chang; Eric D Peterson; Jonathan P Piccini
Journal:  Am Heart J       Date:  2014-02-17       Impact factor: 4.749

Review 2.  [Ablation for atrial fibrillation in the elderly].

Authors:  Clemens Jilek; Thorsten Lewalter
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-01-30

3.  Health-related quality of life changes in patients undergoing repeated catheter ablation for atrial fibrillation.

Authors:  Thomas Pezawas; Robin Ristl; Christoph Schukro; Herwig Schmidinger
Journal:  Clin Res Cardiol       Date:  2015-06-24       Impact factor: 5.460

4.  Effect of catheter ablation versus antiarrhythmic drugs on atrial fibrillation: A meta-analysis of randomized controlled trials.

Authors:  Lei-Zhi Shi; Rui Heng; Shi-Min Liu; Fei-Yan Leng
Journal:  Exp Ther Med       Date:  2015-06-03       Impact factor: 2.447

5.  Procedural success, safety and patients satisfaction after second ablation of atrial fibrillation in the elderly: results from the German Ablation Registry.

Authors:  Thomas Fink; Andreas Metzner; Stephan Willems; Lars Eckardt; Hüseyin Ince; Johannes Brachmann; Stefan G Spitzer; Thomas Deneke; Claus Schmitt; Matthias Hochadel; Jochen Senges; Andreas Rillig
Journal:  Clin Res Cardiol       Date:  2019-04-05       Impact factor: 5.460

6.  Outcomes of catheter ablation versus antiarrhythmic therapy in patients with atrial fibrillation: a systematic review and meta-analysis.

Authors:  Radhika Deshpande; Yasser AlKhadra; Prashanth Singanallur; Albert Botchway; Mohamed Labedi
Journal:  J Interv Card Electrophysiol       Date:  2022-09-03       Impact factor: 1.759

7.  Current Evidence and Recommendations for Rate Control in Atrial Fibrillation.

Authors:  Abhishek Maan; Moussa Mansour; Jeremy N Ruskin; E Kevin Heist
Journal:  Arrhythm Electrophysiol Rev       Date:  2013-04

8.  Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.

Authors:  Benjamin A Steinberg; Anne S Hellkamp; Yuliya Lokhnygina; Jonathan L Halperin; Günter Breithardt; Rod Passman; Graeme J Hankey; Manesh R Patel; Richard C Becker; Daniel E Singer; Werner Hacke; Scott D Berkowitz; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf; Jonathan P Piccini
Journal:  Heart Rhythm       Date:  2014-05-13       Impact factor: 6.343

Review 9.  Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation.

Authors:  Jonathan Nyong; Guy Amit; Alma J Adler; Onikepe O Owolabi; Pablo Perel; David Prieto-Merino; Pier Lambiase; Juan Pablo Casas; Carlos A Morillo
Journal:  Cochrane Database Syst Rev       Date:  2016-11-22

10.  Long-term stroke rates after catheter ablation or antiarrhythmic drug therapy for atrial fibrillation: a meta-analysis of randomized trials.

Authors:  Ya-Ru Zheng; Zhi-Yun Chen; Li-Fang Ye; Li-Hong Wang
Journal:  J Geriatr Cardiol       Date:  2015-09       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.